CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Chemomab Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.17−0.09 (-7.51%)
Close on Oct 19, 2026
- Market cap
- $749.09M
- P/E (TTM)
- 65.0
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 19, 2026 | Before market open | – | $0.00 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | – | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $0.01 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | Before market open | – | $0.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 21, 2024 | Before market open | – | $0.01 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $0.01 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | – | $0.01 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | $0.04 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | $-0.04 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 21, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 12, 2022 | Before market open | – | – | – |
Press releases
Announcements Chemomab Therapeutics filed with the SEC
1 American Depositary Share (ADS) represents 80 Ordinary Shares
EX-99.1 to Form 6-K
CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS
EX-99.2 to Form 6-K
Therapeutics Announces Second Quarter 2026 Financial Results and
EX-99.3 to Form 6-K
Dear Chemomab Therapeutics Ltd. Shareholders:
EX-99.1 to Form 6-K
See Voting Instruction On Reverse Side.
EX-99.2 to Form 6-K
Chemomab Therapeutics Announces Year End and
EX-99.1 to Form 6-K
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and
EX-99.1 to Form 6-K
Ordinary shares no par value
EX-99.1 to Form 6-K
Dear Chemomab Therapeutics Ltd. Shareholders:
EX-99.1 to Form 6-K
See Voting Instruction On Reverse Side.
EX-99.1#2 to Form 6-K
Chemomab Announces New Medical and Clinical Appointments
EX-99.1 to Form 6-K
Dear Chemomab Therapeutics Ltd. Shareholders:
EX-99.1 to Form 6-K
See Voting Instruction On Reverse Side.
EX-99.2 to Form 6-K
Ordinary shares no par value
EX-99.1 to Form 6-K
CM-101 Phase 2 SPRING TRIALPreliminary Topline Results JULY 25, 2024 NASDAQ:
EX-99.2 to Form 6-K
Dear Chemomab Therapeutics Ltd. Shareholders:
EX-99.1 to Form 6-K
See Voting Instruction On Reverse Side.
EX-99.2 to Form 6-K
As of September 30, 2023
EX-99.1 to Form 6-K
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and
EX-99.2 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Dear Chemomab Therapeutics Ltd. Shareholders:
EX-99.1 to Form 6-K